Avalyn Pharma Inc. (AVLN) Debt Components
- 2026-06-30: Long-term Debt, Excluding Current MaturitiesUSD $14.80M; Long-term Line of CreditUSD $15.00M; Long-term DebtUSD $14.80M; Long-Term Debt, Maturity, Year OneUSD $0.00.
- 2026-03-31: Long-term Debt, Excluding Current MaturitiesUSD $14.81M; Long-term Line of CreditUSD $15.00M; Long-term DebtUSD $14.81M; Long-Term Debt, Maturity, Year OneUSD $0.00.
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD $0.00; Long-term Line of CreditUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
Avalyn Pharma Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD | Long-term Line of Credit USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount (Premium), Net USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.80M | $15.00M | $14.80M | $0.00 | $0.00 | $6.00M | $6.00M | $3.00M | $15.00M | $199.00K |
| 2026-03-31 | $14.81M | $15.00M | $14.81M | $0.00 | $0.00 | $6.00M | $6.00M | $3.00M | $15.00M | $192.00K |
| 2025-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |